Challenges and future trends in the treatment of psoriasis

HJ Lee, M Kim - International Journal of Molecular Sciences, 2023 - mdpi.com
Psoriasis is a chronic inflammatory skin disorder, and current treatments include topical
therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate …

New treatment addressing the pathogenesis of psoriasis

M Tokuyama, T Mabuchi - International journal of molecular sciences, 2020 - mdpi.com
Psoriasis is an immune cell-mediated inflammatory skin disease. The interleukin (IL) 23/IL17
axis plays an important role in the development of psoriasis. The effectiveness of biologic …

Comorbidities associated with psoriatic arthritis: review and update

LM Perez-Chada, JF Merola - Clinical Immunology, 2020 - Elsevier
Psoriatic arthritis is an inflammatory arthropathy frequently associated with psoriasis and
several other comorbidities. The goal of this review is to summarize the available evidence …

The role of inflammation in autoimmune disease: a therapeutic target

Y Xiang, M Zhang, D Jiang, Q Su, J Shi - Frontiers in Immunology, 2023 - frontiersin.org
Autoimmune diseases (AIDs) are immune disorders whose incidence and prevalence are
increasing year by year. AIDs are produced by the immune system's misidentification of self …

Drug survival of interleukin (IL)‑17 and IL‑23 inhibitors for the treatment of psoriasis: a retrospective multi‑country, multicentric cohort study

T Torres, L Puig, R Vender, J Yeung… - American Journal of …, 2022 - Springer
Background Drug survival, defined as the length of time from initiation to discontinuation of a
given therapy, allows comparisons between drugs, helps to predict patient's likelihood of …

Anti IL-17 in psoriasis

K Ly, MP Smith, Q Thibodeaux, V Reddy… - Expert review of …, 2019 - Taylor & Francis
Introduction: Psoriasis is a chronic, immune-mediated disease with significant associated
comorbidities. Its pathogenesis is likely multifactorial, however, the interleukin-23/T helper …

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo …

JCC Wei, TH Kim, M Kishimoto, N Ogusu… - Annals of the …, 2021 - ard.bmj.com
Objective To investigate the efficacy and safety of brodalumab, a fully human anti-interleukin-
17 receptor A monoclonal antibody, in patients with axial spondyloarthritis (axSpA). Methods …

Interleukin-17A interweaves the skeletal and immune systems

M Tang, L Lu, X Yu - Frontiers in Immunology, 2021 - frontiersin.org
The complex crosstalk between the immune and the skeletal systems plays an
indispensable role in the maintenance of skeletal homeostasis. Various cytokines are …

Cytokine pathways and investigational target therapies in hidradenitis suppurativa

E Del Duca, P Morelli, L Bennardo… - International journal of …, 2020 - mdpi.com
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting
areas with a high density of apocrine glands and characterized by subcutaneous nodules …

Potential therapeutic value of the STING inhibitors

S Zhang, R Zheng, Y Pan, H Sun - Molecules, 2023 - mdpi.com
The stimulator of interferon genes (STING) is a critical protein in the activation of the immune
system in response to DNA. It can participate the inflammatory response process by …